Skip to main content
Cathay Biotech Inc. logo

Cathay Biotech Inc. — Investor Relations & Filings

Ticker · 688065 ISIN · CNE100004447 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 753 across all filing types
Latest filing 2023-11-10 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 688065

About Cathay Biotech Inc.

https://www.cathaybiotech.com/

Cathay Biotech Inc. specializes in the research, development, and commercial-scale production of bio-based materials through synthetic biology and metabolic engineering. The company’s core portfolio features long-chain diacids (LCDA), bio-based pentanediamine, and high-performance bio-based polyamides, including the Terryl and Ecopent product lines. These materials are utilized across various applications such as automotive components, electronics, consumer goods, and specialized textiles. By leveraging biological manufacturing processes to replace traditional thermochemical methods, the company provides sustainable alternatives to petroleum-derived chemicals. Cathay Biotech focuses on delivering high-performance, low-carbon solutions that support the transition toward a circular economy and reduced environmental impact in global supply chains.

Recent filings

Filing Released Lang Actions
天健会计师事务所（特殊普通合伙）关于上海凯赛生物技术股份有限公司前次募集资金使用情况的鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled as a "前次募集资金使用情况鉴证报告" which translates to "Previous Fundraising Usage Verification Report." It includes detailed sections on the use of previously raised funds, changes in the use of funds, investment projects, and verification by a certified accounting firm. The document references compliance with the China Securities Regulatory Commission guidelines for issuance and fundraising. It contains detailed financial data on fundraising amounts, usage, changes, and investment project statuses. The presence of an auditor's verification report and detailed financial tables about fundraising usage indicates this is a standalone audit-related report focused on fundraising usage verification, not a full annual or interim report. It is not a simple announcement or a brief summary but a comprehensive verification report on fundraising usage. Therefore, the document fits best under the category of Audit Report / Information (AR). 9M 2023
2023-11-10 Chinese
关于变更公司注册资本、修订《公司章程》并办理工商变更登记的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Shanghai Kaisai Biotechnology Co., Ltd. regarding changes in the company's registered capital and amendments to the company's articles of association. It details the board meeting resolutions, the increase in registered capital due to stock incentive plan vesting, and the specific amendments to the articles of association. The document is a formal public announcement about corporate governance changes related to capital and company bylaws, not a full report or financial statement. It does not contain financial statements or detailed financial analysis, nor is it a report publication announcement. This fits the category of Regulatory Filings (RNS) as it is a regulatory announcement about corporate changes that do not fit other specific categories like capital changes (SHA) because it involves amendments to the articles and registration changes, or management changes (MANG). Given the content and length, RNS is the most appropriate classification.
2023-11-10 Chinese
前次募集资金使用情况报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the usage of previously raised funds by Shanghai Kaisai Biotechnology Co., Ltd. It includes specifics on the amount raised, the timing of fund receipt, storage details, changes in fund usage, investment projects, actual investment amounts, and the benefits realized from these investments. The report references regulatory guidelines from the China Securities Regulatory Commission and includes detailed financial figures and project progress updates. The content focuses on the use of capital raised from a prior fundraising event, including changes and actual usage, which aligns with the definition of a Capital/Financing Update (CAP). It is not an announcement of a report publication, nor is it a full annual or interim financial report. It is a comprehensive update on fundraising and capital usage, fitting the CAP category.
2023-11-10 Chinese
关于以集中竞价交易方式回购公司股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is a progress announcement regarding the company's repurchase of its own shares through centralized bidding transactions. It details the number of shares repurchased, prices, total funds used, and references the company's board approval of the repurchase plan. The document is relatively short (1174 characters) and focuses on the share buyback activity, not on financial results or other report types. This matches the definition of a Transaction in Own Shares (POS) filing, which reports on share repurchase activities.
2023-10-31 Chinese
独立董事关于第二届董事会第十四次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from the independent directors of Shanghai Kaisai Biotechnology Co., Ltd. regarding the use of temporarily idle raised funds for cash management. It references compliance with regulatory rules and company articles but does not contain financial statements or detailed financial data. It is a formal opinion related to board matters and fund usage approval, not a full report or announcement of voting results. This fits best under Board/Management Information (MANG) as it relates to board-level decisions and opinions.
2023-10-30 Chinese
关于使用部分暂时闲置募集资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Shanghai Kaisai Biotechnology Co., Ltd. regarding the use of temporarily idle raised funds for cash management. It details the board and supervisory approvals, investment purpose, amount, duration, types of investment products, risk control measures, and opinions from independent directors and sponsors. The document references regulatory approvals and compliance with China Securities Regulatory Commission and Shanghai Stock Exchange rules. It is a formal disclosure about the company's financing fund management activities rather than a financial report or earnings release. The document length is under 5,000 characters and is an announcement of a financing-related decision, not a full report. Therefore, it fits best under Capital/Financing Update (CAP).
2023-10-30 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.